Effects of Early Palliative Care Integration on Patients With Newly Diagnosed Multiple Myeloma

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 17, 2020

Primary Completion Date

October 26, 2022

Study Completion Date

October 26, 2022

Conditions
Multiple Myeloma
Interventions
OTHER

Palliative Care

Early PC Integration - Participants will meet with a member of the outpatient PC team, which consists of board-certified PC physicians, advance practice providers and nurse care coordinators, within three weeks of enrollment. Participants will be scheduled to meet with a PC provider at least once per month. Additional visits may be scheduled at the discretion of participants, oncologists or PC providers. All participants will receive routine oncologic care throughout the study period.

OTHER

FACT-MM questionnaire

FACT-MM questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.

OTHER

HADS questionnaire

HADS questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.

Trial Locations (1)

44195

Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT04248244 - Effects of Early Palliative Care Integration on Patients With Newly Diagnosed Multiple Myeloma | Biotech Hunter | Biotech Hunter